Share on StockTwits

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 1,045,600 shares, a growth of 102.4% from the April 15th total of 516,599 shares, AnalystRatings.NET reports. Based on an average trading volume of 239,934 shares, the days-to-cover ratio is currently 4.4 days. Currently, 6.5% of the shares of the stock are short sold.

A number of analysts have recently weighed in on RARE shares. Analysts at Zacks initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, March 5th. They set a “hold” rating on the stock. Separately, analysts at Cowen and Company initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 25th. They set an “outperform” rating on the stock. Finally, analysts at Morgan Stanley initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 25th. They set an “overweight” rating and a $81.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $77.33.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 34.48 on Monday. Ultragenyx Pharmaceutical has a one year low of $32.62 and a one year high of $69.774. The stock’s 50-day moving average is $43.25 and its 200-day moving average is $47.69. The company’s market cap is $1.036 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings data on Monday, May 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.48. Analysts expect that Ultragenyx Pharmaceutical will post $-1.82 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.